{"id":114,"date":"2023-09-19T11:54:21","date_gmt":"2023-09-19T15:54:21","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/?p=114"},"modified":"2024-03-05T11:57:44","modified_gmt":"2024-03-05T15:57:44","slug":"ftc-warns-drug-companies-about-improper-listings-of-patents-in-orange-book","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/2023\/09\/19\/ftc-warns-drug-companies-about-improper-listings-of-patents-in-orange-book\/","title":{"rendered":"FTC Warns Drug Companies About Improper Listings of Patents in Orange Book"},"content":{"rendered":"<p>On Thursday September 14, 2023, the FTC issued a\u00a0<a href=\"https:\/\/blogs.duanemorris.com\/www.ftc.gov\/system\/files\/ftc_gov\/pdf\/p239900orangebookpolicystatement092023.pdf\" target=\"_blank\" rel=\"noopener\">policy statement<\/a>\u00a0warning brand drug companies that improper listing of patents in the FDA\u2019s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the \u201cOrange Book\u201d could violate Section 5 of the FTC Act.<\/p>\n<p><strong><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2023\/09\/19\/ftc-issues-policy-statement-cautioning-branded-drug-companies-against-improper-orange-book-listings\/\" target=\"_blank\" rel=\"noopener\">Read more on the Duane Morris Life Sciences Law Blog.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Thursday September 14, 2023, the FTC issued a\u00a0policy statement\u00a0warning brand drug companies that improper listing of patents in the FDA\u2019s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the \u201cOrange Book\u201d could violate Section 5 of the FTC Act. Read more on the Duane Morris Life Sciences Law Blog.<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[45,42,16,44,40,34,35],"ppma_author":[5],"class_list":["post-114","post","type-post","status-publish","format-standard","hentry","category-general","tag-drug-manufacturers","tag-fda","tag-ftc","tag-ftc-act","tag-life-sciences","tag-orange-book","tag-patents"],"authors":[{"term_id":5,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts\/114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/comments?post=114"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts\/114\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/media?parent=114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/categories?post=114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/tags?post=114"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/ppma_author?post=114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}